Sinopharm Tech Holdings Limited provides unaudited consolidated earnings guidance for the three months ended 30 September 2022. For the period, the company expects profit attributable to equity holders of the Company of not less than HKD 4.0 million as compared with a loss attributable to equity holders of the Company of approximately HKD 9.4 million for the corresponding period in 2021.
Sinopharm Tech Holdings Limited
Equities
8156
KYG2159V1418
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.115 HKD | 0.00% | -0.86% | -12.88% |
02-29 | Sinopharm Tech Holdings Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 | CI |
2023 | Sinopharm Tech Holdings Limited Announces Management Changes | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.88% | 2.7M | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.70% | 40.7B | |
+24.51% | 32.3B | |
+3.43% | 26.53B | |
+13.67% | 25.02B |
- Stock Market
- Equities
- 8156 Stock
- News Sinopharm Tech Holdings Limited
- Sinopharm Tech Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Three Months Ended 30 September 2022